重组抗HIV V2顶点单克隆抗体(VRC38.01) 人IgG1 Kappa | Syd Labs PA007186

重组抗HIV V2顶点单克隆抗体(VRC38.01) 人IgG1 Kappa Syd Labs PA007186

重组抗HIV V2顶点单克隆抗体(VRC38.01) 人IgG1 Kappa | Syd Labs PA007186

In stock

一键复制

Syd Labs生产的体内实验级重组抗HIV-1 Env V2顶点广谱中和单克隆抗体,克隆号 ‌VRC38.01(又称N90-VRC38.01)‌,由NIH疫苗研究中心(VRC)从HIV-1慢性感染者供体N90的记忆B细胞中分离。与PG9、PGT145、CAP256-VRC26等经典V2顶点bNAb依赖超长CDRH3(24–38 aa)穿透糖盾不同,‌VRC38.01采用仅16个氨基酸的”非突出环”(non-protruding CDRH3)‌,以侧链-侧链相互作用”偏中心”结合V1V2顶点,识别N156/N160糖链及V2 β-链C段,代表V2顶点结合的全新免疫遗传学解决方案,为HIV种系靶向疫苗设计提供了一条更常规B细胞路径的原型模板。该抗体在208株多亚型假病毒板中和约30%毒株,无自身反应性,无HEp-2细胞/心磷脂交叉反应。本品采用人IgG1κ恒定区重组表达,经LAL内毒素<1 EU/mg、SDS-PAGE纯度>95%、0.2 μm无菌过滤,适合小鼠/恒河猴SHIV攻毒、被动转移保护、bNAb联合疗法、Env结构与疫苗免疫原评估等体内外实验。

产品参数

货号 PA007186
产品名称重组抗HIV V2顶点单克隆抗体(VRC38.01) 人IgG1 Kappa | Syd Labs PA007186
英文名 In Vivo Grade Recombinant Anti-HIV V2 Apex Monoclonal Antibody (Clone VRC38.01), Human IgG1 Kappa
供货商名称 Syd Labs, Inc.
品牌名 Syd Labs
克隆号 VRC38.01
同种型 人 IgG1,Kappa
特异性 HIV V2顶点(V2 apex)
抗体形式 0.2 μm 过滤的 1× PBS 溶液
内毒素 <1 EU/mg(LAL 法测定)
纯度 >95%(还原性 SDS-PAGE)
运输 冰袋运输,收到后请立即按推荐条件储存
稳定性与存储 使用手动除霜冰箱并避免反复冻融循环。2-8℃自收到之日起可保存1个月;-20℃至-70℃自收到之日起可保存12个月,建议分装保存
产品咨询 Syd Labs在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系Syd Labs中国代理商。
关于Syd Labs产品如果有任何技术或其它问题,欢迎随时联系Syd Labs国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理)
应用详情 ELISA、Western blot(蛋白免疫印迹)、免疫组化(IHC)、流式细胞术(FC),以及多种体外(in vitro)和体内(in vivo)功能实验。

文献

重组抗HIV V2顶点单克隆抗体(VRC38.01) 人IgG1 Kappa,体内实验级(In Vivo Grade Recombinant Anti-HIV V2 Apex Monoclonal Antibody (Clone VRC38.01), Human IgG1 Kappa)

重组抗HIV V2顶点单克隆抗体背景知识:

‌HIV-1 V2顶点广谱中和抗体与VRC38.01的发现‌

HIV-1包膜蛋白(Env)三聚体顶端的V1V2区是广谱中和抗体的关键靶点之一。自2009年PG9/PG16被发现以来,已报道的V2顶点bNAb(包括PG9、PGT145、CH01、CAP256-VRC26系列、PGDM1400等)几乎都依赖‌长度异常突出的CDRH3环(24–38 aa)‌穿透糖盾到达N160糖链-多肽复合表位,而这类长CDRH3在人类初始B细胞库中出现频率极低,给疫苗诱导带来巨大障碍。

2017年,NIH疫苗研究中心Cale、Gorman、Binley、Kwong、Mascola团队在 Immunity 上报道,以HIV-1样颗粒(VLP,在天然膜环境下展示构象天然的Env三聚体)和稳定化的SOSIP gp140三聚体作为B细胞探针,从供体N90(北美B亚型HIV-1感染者,血清具有广谱中和活性)中分离出一组全新的V2顶点中和抗体谱系 ‌N90-VRC38.01-.11‌。代表性成熟抗体VRC38.01采用IGHV3-13*01重链胚系,其CDRH3仅16个氨基酸(长度接近人类抗体平均水平,属”非突出环”),却依然能通过VRC38.01重链CDRH3/CDRH2与V1V2之间的‌侧链-侧链相互作用‌(side-chain-to-side-chain contacts)缩短穿越糖盾所需距离,以‌”偏中心”(off-center)‌姿态结合在三聚体顶点远离三重对称轴的一侧,主要识别N156糖链、N160糖链及V2 β-链C段(Strand C),且与N130糖链存在空间冲突,这一特征决定了其对N160糖链与V2碱性残基的依赖性,同时解释了其对E168K突变不敏感等与PG9/CH01类不同的中和谱特征。

‌在HIV疫苗设计中的意义‌

VRC38谱系最突出的价值在于它揭示了V2顶点bNAb‌不必‌依靠长CDRH3环——16 aa的平均长度CDRH3在人类初始B细胞库中的出现频率远高于超长CDRH3,意味着VRC38类抗体更易于通过疫苗免疫诱导。晶体结构与负染电镜显示VRC38.01可在一个三聚体上以1~2个Fab的化学计量比结合,IgG形式双价结合使其中和效力比单价Fab提高17–170倍。指纹分析(neutralization fingerprinting)进一步提示VRC38类特异性在HIV感染者中可能普遍存在,使其成为HIV种系靶向(germline-targeting)V2 apex疫苗的重要原型模板之一。

‌PA007186的质量特征‌

本品PA007186为Syd Labs In Vivo Grade系列产品,按体内实验严格标准生产:SDS-PAGE纯度>95%,LAL内毒素<1 EU/mg,经0.2 μm无菌过滤、1× PBS配方,不含防腐剂,可直接用于小鼠、恒河猴等小动物模型的被动免疫保护、SHIV攻毒、药物代谢/半衰期评估、bNAb鸡尾酒(如与VRC01、10-1074、3BNC117、10E8等联用)以及Env免疫原评价等体内外实验。

重组抗HIV V2顶点单克隆抗体部分参考文献:

1.Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop
Evan M. Cale, Jason Gorman, Nathan A. Radakovich, Ema T. Crooks, Keiko Osawa, Tommy Tong, Jiaqi Li, Raju Nagarajan, Gabriel Ozorowski, David R. Ambrozak, Mangai Asokan, Robert T. Bailer, Anthony K. Bennici, Xuejun Chen, Nicole A. Doria-Rose, Aliaksandr Druz, Yu Feng, M. Gordon Joyce, Mark K. Louder, Sijy O’Dell, Courtney Oliver, Marie Pancera, Mark Connors, Thomas J. Hope, Thomas B. Kepler, Richard T. Wyatt, Andrew B. Ward, Ivelin S. Georgiev, Peter D. Kwong, John R. Mascola, James M. Binley
Immunity. 2017;46(5):777–791.e10. PMCID: PMC5512451 PMID: 28514685 DOI: 10.1016/j.immuni.2017.04.011
“Most HIV-1-specific neutralizing antibodies isolated to date exhibit unusual characteristics that complicate their elicitation. Neutralizing antibodies that target the V1V2 apex of the HIV-1 envelope (Env) trimer feature unusually long protruding loops, which enable them to penetrate the HIV-1 glycan shield. … Here, we isolated a lineage of Env apex-directed neutralizing antibodies, N90-VRC38.01-11, by using virus-like particles and conformationally stabilized Env trimers as B cell probes. A crystal structure of N90-VRC38.01 with a scaffolded V1V2 revealed a binding mode involving side-chain to side-chain interactions that reduced the distance the antibody loop must traverse the glycan shield, thereby facilitating V1V2 binding via a non-protruding loop. The N90-VRC38 lineage thus identifies a solution for V1V2-apex binding that provides a more conventional B cell pathway for vaccine design.”

2.Crystal Structure of the Human Fab VRC38.01, an HIV-1 V1V2-Directed Neutralizing Antibody Isolated from Donor N90
Jason Gorman, Evan M. Cale, Peter D. Kwong
PDB. 2016; 5EWI. DOI: 10.2210/pdb5EWI/pdb
“Crystal structure of the antigen-binding fragment (Fab) of VRC38.01 in the free (unliganded) state, determined to high resolution, providing the structural reference for the N90-VRC38 lineage that uses a non-protruding, average-length CDRH3 to recognize the HIV-1 V1V2 apex, thereby offering a more conventional vaccine-inducible template relative to long-loop V2 apex bNAbs such as PG9 and PGT145.”

3.Structural Basis for Broad HIV-1 Neutralization by the V1V2-Directed CAP256-VRC26 BnAb Lineage
Nicole A. Doria-Rose, et al.
Cell Rep. 2014;6(4):699–711. PMCID: PMC3885649 PMID: 24529704
“The V1V2 domain of the HIV-1 envelope trimer is a major target for broad and potent neutralizing antibodies. Here we report the isolation of a lineage of V1V2-directed antibodies, CAP256-VRC26, from donor CAP256. These antibodies demonstrate extraordinary neutralization breadth and potency that are dependent on an anionic, sulfated, 36-residue CDRH3 that penetrates the glycan shield to contact both protein and glycan at the trimer apex—providing a structural benchmark against which VRC38’s alternative, non-protruding-loop mode of apex recognition can be compared.”

4.Structure of HIV-1 gp120 V1/V2 Domain with Broadly Neutralizing Antibody PG9
Jason Gorman, et al.
Science. 2011;333(6044):844–847. PMCID: PMC3243115 PMID: 21737701
“Quaternary-structure-specific epitopes on the HIV-1 envelope trimer are major targets for vaccine design. We report the crystal structure of the V1/V2 domain of HIV-1 gp120 in complex with PG9, a broadly neutralizing antibody. The structure shows a β-strand–rich V1/V2 scaffold with N-linked glycans at positions Asn160 and Asn156/Asn173, which form the integrin-binding site and the PG9 epitope—defining the conserved N160-glycan-dependent V2 apex motif that VRC38.01 also recognizes via its own distinct binding geometry.”

5.HIV-1 Broadly Neutralizing Antibody VRC26.26 and Its Structural Insight into Recognition of the V1V2 Apex
Priyanthi N.P. Gnanakaran, et al.
PLoS Pathog. 2016;12(3):e1005538. PMCID: PMC4722598 PMID: 26934335
“The V1V2 apex of HIV-1 Env remains one of the most clinically important sites of vulnerability. This study details the maturation pathway, functional features and structural recognition of CAP256-VRC26.26 and related members of the lineage, and highlights how the dense N160-centered glycan canopy and conserved lysine-rich β-strand C segment shape epitope accessibility—context that clarifies the ‘off-center’, N156/N160-dependent footprint and the moderate breadth (~30% across 208 isolates) observed for VRC38.01.”